甲基吩噻嗪-10-基甲酮 | 1628-29-1

• 物质功能分类: 化学试剂 - 有机试剂 - 肼
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 中文名称: 甲基吩噻嗪-10-基甲酮
• 英文名称: 10-acetyl-10H-phenothiazine
• 英文别名: 10-acetylphenothiazine；N-acetylphenothiazine；1-(10H-phenothiazin-10-yl)ethan-1-one；1-phenothiazin-10-ylethanone
• CAS: 1628-29-1
• 化学式: C₁₄H₁₁NOS
• 分子量: 241.313
• InChiKey: DNVNQWUERFZASD-UHFFFAOYSA-N

物化性质

• 熔点：
  198 °C(Solv: ethanol (64-17-5))
• 沸点：
  470.6±15.0 °C(Predicted)
• 密度：
  1.284±0.06 g/cm3(Predicted)
• 溶解度：
  26.4 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  45.6
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934300000
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温和干燥环境

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Methyl phenothiazin-10-yl ketone
CAS-No. : 1628-29-1
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No 1272/2008
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C14H11NOS
Molecular Weight : 241,31 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Sulphur oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Avoid
breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 3,28
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
Prolonged or repeated exposure may cause allergic reactions in certain sensitive individuals. The
preceding data, or interpretation of data, was determined using Quantitative Structure Activity Relationship
(QSAR) modeling.
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  甲基吩噻嗪-10-基甲酮 在 三乙基硼 、 水 、 potassium hydroxide 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 25.0h， 生成 吩噻嗪
  参考文献：
  名称：

  组合KOH / BEt 3催化剂用于芳香族羧酰胺的选择性脱氨加氢硼化反应以构建发光体

  摘要：

  酰胺选择性催化C–N键裂解为增值胺产品是一种理想的但具有挑战性的转化。含有亚氨基二苄基基序的分子普遍存在于药物分子和功能材料中。在这里，我们建立了一种组合的KOH / BEt 3催化剂，用于将酰基-亚氨基二苄基衍生物（包括非杂环羧酰胺）进行脱氨基硼氢化成相应的胺。这种新颖的无过渡金属的方法也被用于氯米帕明和发光体的构建。

  DOI：

  10.1021/acs.orglett.0c03033
• 作为产物：
  描述：

  2-((2-bromophenyl)thio)aniline 在 chloro-(2-dicyclohexylphosphino-2’,6’-diisopropoxy-1,1‘-biphenyl)[2-(2-aminoethyl)phenyl] palladium(ll) methyl-tert-butyl ether adduct 、 sodium t-butanolate 、 2-二环己基磷-2',6'-二异丙氧基-1,1'-联苯 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 甲基吩噻嗪-10-基甲酮
  参考文献：
  名称：

  通过芳烃与 S-(邻溴芳基)-S-甲基硫亚胺的直接硫胺化和随后的分子内 Buchwald-Hartwig 胺化合成多种吩噻嗪

  摘要：

  通过芳炔中间体与 S-(邻溴芳基)-S-甲基硫亚胺的直接硫胺化和随后的分子内...

  DOI：

  10.1246/cl.180304
• 作为试剂：
  描述：

  3-氯乙酰苯胺 在 甲基吩噻嗪-10-基甲酮 、 dichloro(pentamethylcyclopentadienyl)rhodium (III) dimer 、 silver(I) acetate 、 copper(II) bis(trifluoromethanesulfonate) 、 乙酸乙酯 、 potassium hydroxide 作用下， 反应 24.0h， 生成 氯丙嗪
  参考文献：
  名称：

  One-Pot Tandem Access to Phenothiazine Derivatives from Acetanilide and 2-Bromothiophenol via Rhodium-Catalyzed C–H Thiolation and Copper-Catalyzed C–N Amination

  摘要：

  DOI：

  10.1021/acs.joc.1c00403

文献信息

• Catalyst composition for hydrogenation and method for hydrogenation using the same
  申请人：Asahi Kasei Chemicals Corporation

  公开号：US10016749B2

  公开（公告）日：2018-07-10

  A catalyst composition for hydrogenation including (A) to (D), in which a mass ratio ((C)/(A)) is 0.1 to 4.0 and a mass ratio ((D)/(A)) is 0.01 to 1.00, (A): a titanocene compound represented by formula (1), (wherein R5 and R6 are any group selected from hydrogen, a hydrocarbon group having 1 to 12 carbon atoms, an aryloxy group, an alkoxy group, a halogen group, and a carbonyl group. R1 and R2 are any group selected from the group consisting of hydrogen and a hydrocarbon group having 1 to 12 carbon atoms, and R1 and R2 are not all hydrogen atoms or all a hydrocarbon group having 1 to 12 carbon atoms), (B): a reductant formed from a compound containing an element selected from the elements Li, Na, K, Mg, Zn, Al, and Ca, (C): an unsaturated compound having a molecular weight of 400 or less, and (D): a polar compound.

  一种用于加氢的催化剂组合物，包括(A)至(D)，其中质量比((C)/(A))为0.1至4.0，质量比((D)/(A))为0.01至1.00， (A)：由公式(1)表示的钛环戊二烯基化合物， （其中R5和R6是从氢、具有1至12个碳原子的烃基、芳氧基、烷氧基、卤素基和羰基中选择的任何基团。R1和R2是从氢和具有1至12个碳原子的烃基组成的组中选择的任何基团，且R1和R2不全是氢原子或全部为具有1至12个碳原子的烃基）， (B)：由含有选自Li、Na、K、Mg、Zn、Al和Ca元素的化合物的还原剂形成， (C)：分子量400或以下的非饱和化合物，以及 (D)：极性化合物。
• Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase
  申请人：Forum Pharmaceuticals, Inc.

  公开号：US20170000749A1

  公开（公告）日：2017-01-05

  This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

  这份披露涉及用于抑制组蛋白去乙酰化酶和治疗认知障碍或缺陷的化合物。更具体地，该披露提供了公式（I）的化合物 其中 Q、J、L和Z如规范中所定义。
• Design of Novel Potent Antihyperlipidemic Agents with Antioxidant/Anti-inflammatory Properties: Exploiting Phenothiazine’s Strong Antioxidant Activity
  作者：Alexios N. Matralis、Angeliki P. Kourounakis

  DOI：10.1021/jm401842e

  日期：2014.3.27

  Because atherosclerosis is an inflammatory process involving a series of pathological events such as dyslipidemia, oxidative stress, and blood clotting mechanisms, we hereby report the synthesis and evaluation of novel compounds in which antioxidant, anti-inflammatory, and squalene synthase (SQS) inhibitory/hypolipidemic activities are combined in simple molecules through design. The coupling of two

  由于动脉粥样硬化是涉及一系列病理事件（例如血脂异常，氧化应激和血液凝固机制）的炎症过程，因此我们在此报告合成和评估其中抗氧化剂，抗炎剂和角鲨烯合酶（SQS）抑制/通过设计将降血脂活性结合在简单的分子中。两种不同药效基团的偶联产生化合物1 – 12，与亲本铅结构（即，降血脂的2-羟基-2-芳基-（苯并）氧杂（或硫杂）嗪和抗氧化剂吩噻嗪）相比，其生物学特性得到了显着改善。大多数衍生物强烈抑制体外微粒体脂质和LDL过氧化，表现出有效的自由基清除活性。它们在急性和高脂诱导的高脂血症动物模型中进一步显着抑制SQS活性，并在体内显示出显着的抗血脂异常活性。最后，几种化合物在体外显示出抗炎活性，抑制了环氧合酶（COX-1 / 2）的活性。新化合物的多峰性质，尤其是其组合的抗氧化剂/ SQS / COX抑制活性使它们成为用于进一步评估动脉粥样硬化的有趣的先导化合物。
• 一种二取代酰胺衍生物脱羰加氢的绿色新方 法
  申请人：台州学院

  公开号：CN107337573B

  公开（公告）日：2020-09-01

  本发明涉及一种高效、高选择性的二取代酰胺衍生物的脱羰加氢反应的绿色新方法。首次以非金属化合物三乙基硼作为催化剂，在温和条件下即可方便的催化N,N‑二芳基取代酰胺及其衍生物与廉价易得的有机硅试剂选择性制备二级有机胺类产品。与传统方法相比，该新方法普遍具备底物普适性广、官能团兼容性优秀、操作简单等优势。首次实现以有机硅试剂作为还原剂使酰胺类化合物发生脱羰加氢反应，为酰胺及其衍生物的还原，特别是有机发光二极管(OLEDs)材料单元‑二芳基胺类化合物的实验室制备或工业生产提供了一种全新的“绿色”反应策略。
• N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions
  申请人：Antel Jochen

  公开号：US20070149512A1

  公开（公告）日：2007-06-28

  The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and related or other conditions.

  本发明涉及具有化学式I的新型N-磺胺基哌啶酰胺及其生理上可接受的酸盐，包括含有它们的药物组合物，其制备方法，以及用于治疗肥胖及其伴随和/或继发疾病以及相关或其他病症的用途。

表征谱图